Section Arrow
Quote
MNPR.NASDAQ
- Monopar Therapeutics Inc
Quotes are at least 15-min delayed:2026/07/10 21:40 EDT
Regular Hours
Last
 106.6
+2.1 (+2.01%)
Day High 
107.41 
Prev. Close
104.5 
1-M High
112.57 
Volume 
149.28K 
Bid
108.73
Ask
168.24
Day Low
97.97 
Open
103.28 
1-M Low
58.01 
Market Cap 
700.05M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 95.14 
20-SMA 81.24 
50-SMA 68.6 
52-W High 112.57 
52-W Low 29.18 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.93/-1.37
Enterprise Value
700.21M
Balance Sheet
Book Value Per Share
20.21
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ELABPmgc Holdings Inc1.12+0.06+5.66%-- 
RXRXRecursion Pharmaceuticals3.56-0.2-5.32%-- 
VYNEVYNE Therapeutics0.6376-0.0344-5.12%-- 
HUMAHumacyte0.6937-0.0066-0.94%-- 
GOSSGossamer Bio0.1697-0.0053-3.03%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.